Clinical Trial Update: Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial exploring switching stable transplant recipients from mycophenolate mofetil to enteric-coated mycophenolate sodium due to gastrointestinal side ef…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation
• Liver Transplantation

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• MYFORTIC (MYCOPHENOLIC ACID)

Snippet

Sponsor: Novartis | Conditions: Kidney Transplantation, Liver Transplantation | Phase 4 | Status: COMPLETED